Dr. Reddy’s dermatologicals
Executive Summary
The Indian drugmaker plans to launch three branded dermatological products in the U.S. by the end of 2009 through its newly-established Bridgewater, N.J.-based Promius Pharma subsidiary. The products, which were in-licensed and co-developed, include: EpiCeram skin barrier emulsion for atopic dermatitis, Scytera foam for psoriasis and Promiseb cream for seborrheic dermatitis. Other topical products are in development. Dr. Reddy's established Promius as a platform for its U.S. branded specialty drug business (1PharmAsia News, Aug. 19, 2008)
You may also be interested in...
New Face For Dr Reddy’s Dermatology Business
MUMBAI - In what could be a significant push to its dermatology business in the U.S., Dr Reddy's Labs has carved out a new company - Promius Pharma to establish a distinct identity for its branded specialty products
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.